Rocket Pharmaceuticals to Join Russell 3000® and 2000® Indexes22-Jun-2018
Press release on Rocket Pharma: Rocket Pharmaceuticals to Join Russell 3000® and 2000® Indexes
NEW YORK--(BUSINESS WIRE)--Jun. 22, 2018-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, announced that the Company will join the broad-market Russell 3000® and Russell 2000®Indexes. The newly reconstituted indexes take effect after the close on Friday, June 22, 2018.
Russell US Indexes are widely used by investment managers and institutional investors as the basis for index funds and as benchmarks for active investment strategies. Approximately
$9 trillionin assets are benchmarked against Russell US Indexes. Russell US Indexes are part of FTSE Russell, a leading global index provider. Rocket’s addition to these indexes will increase the Company’s already growing visibility and presence with institutional investors and greater financial community.
Annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of
May 11, ranking them by total market capitalization. Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell US Indexes primarily by objective, market-capitalization rankings and style attributes.
For more information on the Russell 3000® Index and the Russell US Indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.
Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc.(NASDAQ: RCKT) (“Rocket”) is an emerging, clinical-stage biotechnology company focused on developing first-in-class gene therapy treatment options for rare, devastating diseases. Rocket’s multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. Rocket's lead clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. Preclinical studies of additional bone marrow-derived disorders are ongoing and target Pyruvate Kinase Deficiency (PKD), Leukocyte Adhesion Deficiency-I (LAD-I) and Infantile Malignant Osteopetrosis (IMO). Rocket is also developing an AAV-based gene therapy program for an undisclosed rare pediatric disease. For more information about Rocket, please visit www.rocketpharma.com.
SOURCE Rocket Pharma